Savira, F.Magaye, R.Scullino, C.V.Flynn, B.L.Pitson, S.M.Anderson, D.Creek, D.J.Hua, Y.Xiong, X.Huang, L.Liew, D.Reid, C.Kaye, D.Kompa, A.R.Wang, B.H.2022-05-302022-05-302021Toxicology Letters, 2021; 350:133-1420378-42741879-3169https://hdl.handle.net/2440/135286Abstract not availableen© 2021 Elsevier B.V. All rights reserved.Uremic toxinsDihydroceramide desaturase 1Des1 inhibitorSphingolipidsAnimalsHumansRatsRats, Sprague-DawleyUremiaCardiovascular DiseasesOxidoreductasesSphingolipidsEnzyme InhibitorsModels, AnimalToxins, BiologicalRenal Insufficiency, ChronicSphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibitionJournal article10.1016/j.toxlet.2021.07.0122022-05-30583040Pitson, S.M. [0000-0002-9527-2740]Liew, D. [0000-0002-0131-623X] [0000-0003-2064-181X]